Piper Sandler Maintains Overweight on AnaptysBio, Raises Price Target to $95

Benzinga Newsdesk www.benzinga.com Positive 83.5%

Neg 0% Neu 0% Pos 83.5%

Piper Sandler analyst Yasmeen Rahimi maintains AnaptysBio (NASDAQ:ANAB) with a Overweight and raises the price target from $67 to $95.